Clinical Implications of Having Reduced Mid Forced Expiratory Flow Rates (FEF_25-75), Independently of FEV1, in Adult Patients with Asthma

<div><p>Introduction</p><p>FEF_25-75 is one of the standard results provided in spirometry reports; however, in adult asthmatics there is limited information on how this physiological measure relates to clinical or biological outcomes independently of the FEV₁ or the FEV₁/FVC ratio.</p><p>Purpose</p><p>To determine the association between Hankinson’s percent-predicted FEF_25-75 (FEF_25-75%) levels with changes in healthcare utilization, respiratory symptom frequency, and biomarkers of distal airway inflammation.</p><p>Methods</p><p>In participants enrolled in the Severe Asthma Research Program 1–2, we compared outcomes across FEF_25-75% quartiles. Multivariable analyses were done to avoid confounding by demographic characteristics, FEV₁, and the FEV₁/FVC ratio. In a sensitivity analysis, we also compared outcomes across participants with FEF_25-75% below the lower limit of normal (LLN) and FEV₁/FVC above LLN.</p><p>Results</p><p>Subjects in the lowest FEF_25-75% quartile had greater rates of healthcare utilization and higher exhaled nitric oxide and sputum eosinophils. In multivariable analysis, being in the lowest FEF_25-75% quartile remained significantly associated with nocturnal symptoms (OR 3.0 [95%CI 1.3–6.9]), persistent symptoms (OR 3.3 [95%CI 1–11], ICU admission for asthma (3.7 [1.3–10.8]) and blood eosinophil % (0.18 [0.07, 0.29]). In the sensitivity analysis, those with FEF_25-75% </p><p>Conclusions</p><p>After controlling for demographic variables, FEV₁ and FEV₁/FVC, a reduced FEF_25-75% is independently associated with previous ICU admission, persistent symptoms, nocturnal symptoms, blood eosinophilia and bronchial hyperreactivity. This suggests that in some asthmatics, a reduced FEF_25-75% is an independent biomarker for more severe asthma.</p>